Last reviewed · How we verify
EPA / DHA / Alpha-Tocopherol — Competitive Intelligence Brief
phase 3
Nutritional supplement / Omega-3 fatty acid combination
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
EPA / DHA / Alpha-Tocopherol (EPA / DHA / Alpha-Tocopherol) — Helse Stavanger HF. A combination of omega-3 fatty acids (EPA and DHA) and vitamin E that reduces inflammation and oxidative stress to support cardiovascular and metabolic health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| EPA / DHA / Alpha-Tocopherol TARGET | EPA / DHA / Alpha-Tocopherol | Helse Stavanger HF | phase 3 | Nutritional supplement / Omega-3 fatty acid combination |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Nutritional supplement / Omega-3 fatty acid combination class)
- Helse Stavanger HF · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- EPA / DHA / Alpha-Tocopherol CI watch — RSS
- EPA / DHA / Alpha-Tocopherol CI watch — Atom
- EPA / DHA / Alpha-Tocopherol CI watch — JSON
- EPA / DHA / Alpha-Tocopherol alone — RSS
- Whole Nutritional supplement / Omega-3 fatty acid combination class — RSS
Cite this brief
Drug Landscape (2026). EPA / DHA / Alpha-Tocopherol — Competitive Intelligence Brief. https://druglandscape.com/ci/epa-dha-alpha-tocopherol. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing